

2019 Reference Manual Updates

(January 2019 to date)

The enclosed Client Grams include updated and supplemental information to our most recently published Reference Manual (2019) and are intended to be incorporated into or filed with your Reference Manual until the next annual edition is available.

You will receive all future Client Grams with your laboratory reports. If you would like to receive Client Grams via email, please contact your Account Manager or email us at SQLMarketing@SonoraQuest.com.

Please note these changes in your Reference Manual to ensure you have the most accurate test information. You may also visit SonoraQuest.com to use our Searchable Test Directory.

If you have any questions please call our Customer Solutions Department at 602.685.5285 or 520.784.8050.

REMINDER: Discontinuation of Quantiferon® TB Gold Three-Tube Test

Test 905108	Quantiferon® TB Gold
Effective:	12/17/18
Comment:	Test will be discontinued. Please see below for new testing information and changes in the Quantiferon collection kits and supply numbers.

NEW ASSAY:

Test 906935	Quantiferon® TB Gold Plus													
Specimen:	<p>Do not collect on Sundays. For rural areas, collect after 11:00 a.m., Monday through Friday.</p> <p>Using a Quantiferon collection kit (supply #38933), collect 1 mL room temperature (0.8 mL min.) whole blood in each of the following tubes: QFT-Nil control (gray cap, white ring) tube; QFT-TB1 antigen (green cap, white ring) tube; QFT-TB2 antigen (yellow cap, white ring) tube; QFT-Mitogen control (purple cap, white ring) tube. Immediately after filling the tubes, shake them 10 times just firmly enough to ensure the entire surface of the tube is coated with blood, to solubilize antigens on tube walls.</p> <p>Note: Specimen collection locations >3350 feet above sea level should use the Quantiferon collection kit (supply #38934) designed for “High Altitude” (tubes with gold ring on top).</p> <p>Samples must be received by lab within 12 hours of collection and incubated by lab within 16 hours of collection. Apply the neon green Quantiferon label provided with your collection kit to the outside of the specimen transport bag. Do not spin/centrifuge samples.</p>													
Method:	Immunoassay													
Reference Range:	Negative													
Setup:	Days: Monday - Sunday													
Reports:	5-7 Days													
CPT*:	86480													
Price:	Client: \$ 265.00 Patient: \$265.00													
Interface Mapping:	<table border="1"> <thead> <tr> <th>Result Code</th> <th>Result Name</th> </tr> </thead> <tbody> <tr> <td>10906935</td> <td>QuantiFERON-TB Plus, 4T</td> </tr> <tr> <td>20906935</td> <td>NIL</td> </tr> <tr> <td>30906935</td> <td>Mitogen-NL</td> </tr> <tr> <td>40906935</td> <td>TB1-NIL</td> </tr> <tr> <td>50606935</td> <td>TB2-NIL</td> </tr> </tbody> </table>	Result Code	Result Name	10906935	QuantiFERON-TB Plus, 4T	20906935	NIL	30906935	Mitogen-NL	40906935	TB1-NIL	50606935	TB2-NIL	
Result Code	Result Name													
10906935	QuantiFERON-TB Plus, 4T													
20906935	NIL													
30906935	Mitogen-NL													
40906935	TB1-NIL													
50606935	TB2-NIL													
Comment:	Please note transport temperature is room temperature. Specimens will be shipped refrigerated after incubation and centrifugation by Sonora Quest Laboratories.													

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Client Grams include updated and supplemental laboratory information. Please access our online Test Directory at www.SonoraQuest.com for the most current information.

DISCONTINUED TEST:

Test 14401	Estrone Sulfate
Effective:	12/10/18
Comment:	Test has been discontinued by the referral laboratory. Samples submitted prior to 12/10/18 will be tested. Alternative testing is being investigated and an update will be sent as soon as it is available.

ANNOUNCEMENT: Scheduled Application Server Maintenance

On Sunday, December 16, 2018, Sonora Quest Laboratories will be performing application server maintenance. As a result, all computer systems will be unavailable beginning at 6:00 p.m. until approximately 11:00 p.m.

During this period, our Client Services Representatives will not have access to computerized information or patient results. All reporting will resume by normal processes once our systems are operational. Quantum (formerly Care360) users will have uninterrupted access to patient results that were completed prior to 6:00 p.m. Sunday. Quantum will be updated with results completed during the down-time once the server maintenance is completed.

STAT courier services and STAT testing will remain available during this time and will be reported manually by phone via our established down-time processes.

During the down-time, please contact us as follows:

- Client Services: 602.685.5050
- Logistics (for pick-ups including Mobile Diagnostic Services STAT phlebotomy requests): 602.685.5052

ANNOUNCEMENT: Patient Service Center Closure and Relocation

Our Patient Service Center located at 9305 W. Thomas Rd., #300, in Phoenix will be closing at 4 p.m. on Wednesday, December 26, 2018 and relocating to a new site located at 9321 W. Thomas Rd., #105, in Phoenix on Wednesday, January 2, 2019. Your patients can view all of our locations and schedule appointments on their desktop or mobile device at SonoraQuest.com.

REMINDER: Source and Specimen Requirements for Influenza A/B, Rapid Screen and Respiratory Syncytial Virus, Rapid Screen

Please note nasopharyngeal swab in viral transport media or nasopharyngeal wash or aspirate in sterile containers or tubes without additive are the only acceptable sources and specimens for the following tests:

- Test 903345 - Influenza A/B, Rapid Screen
- Test 904248 - Influenza A/B, Rapid Screen w/Reflex Flu Culture/DFA
- Test 904245 - Influenza A/B, Rapid Screen w/Reflex Virus Culture/DFA
- Test 903346 - Respiratory Syncytial Virus, Rapid Screen

Nasopharyngeal swab in viral transport media is the only acceptable source and specimen for the following test:

- Test 906336 - Influenza A/B and RSV, Qualitative, Real-Time RT-PCR

Please indicate source on specimen and on test requisition. **Unacceptable specimens are: nasal swab, nasal aspirate or wash.**

Client Grams include updated and supplemental laboratory information. Please access our online Test Directory at www.SonoraQuest.com for the most current information.

DISCONTINUED TESTS:

Test 5030 Test 2070	Creatine Kinase, MB Fraction Creatine Kinase, Total and MB
Effective:	1/21/19
Comment:	<p>Tests will be discontinued. The recommended alternative testing is test 902303 – Troponin T. Please note that the following profiles containing these tests will also be discontinued:</p> <p>801081 – CK, CK-MB, Myoglobin, Troponin T 802503 – CK-MB, CPK, Troponin T 803906 – CMP, CBC, Lipid, BNP, CK, CK-MB, Homocysteine, Troponin T</p> <p>Prior to the development of cardiac troponin assays, creatine kinase - myocardial band (CK-MB) was often useful to provide early evidence of myocardial injury. However, in contrast to modern cardiac troponin assays, CK-MB is much less sensitive for the detection of myocardial injury than troponin, requiring larger amounts of tissue injury to allow for its detection. Furthermore, it has lower specificity than troponin, with production/release of CK-MB in skeletal muscle occurring under some physiological and pathological conditions.</p> <p>In 2012, the Third Universal Definition of Acute Myocardial Infarction (AMI) was released, in which cardiac troponin was deemed as the preferred biomarker for the diagnosis of AMI¹. This recommendation was endorsed by the American College of Cardiology Foundation (ACCF), the European Society of Cardiology (ESC), the American Heart Association (AHA) and the World Heart Federation (WHF). Moreover, in 2014, AHA/ACC guidelines concluded that CK-MB is not useful in the diagnosis of ACS (Class III, Level of Evidence: A).² While CK-MB has been historically used for other purposes, to include detecting MI after percutaneous coronary intervention, estimating infarct size, and diagnosing reinfarction, its utility in these aspects remains controversial or has been demonstrated to be adequately replaced with cardiac troponin.^{3,4}</p> <p>1. Thygesen K, et al. Third Universal Definition of Myocardial Infarction. <i>J Am Coll Cardiol</i>. 2012; 60:1581-1598 2. Amsterdam EA, et al. AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014; 64:e139-e228 3. Saenger AK, Jaffe AS. Requiem for a Heavyweight: The Demise of Creatine Kinase-MB. <i>Circulation</i>. 2008;118:2200-2206 4. Jaffe AS, Morrow DA. Biomarkers of Cardiac Injury Other than Troponin. In: Saperia GM, ed. UpToDate. Waltham Mass.: UpToDate; 2018. www.uptodate.com. Accessed August 24, 2018.</p>

CORRECTION:

The interface mapping for TB2-NIL provided in Client Gram volume 43 was incorrect. The correct result code is provided below.

Test 906935	Quantiferon® TB Plus	
Interface Mapping:	Result Code 10906935 20906935 30906935 40906935 50906935	Result Name QuantiFERON-TB Plus, 4T NIL Mitogen-NL TB1-NIL TB2-NIL